Nexus Biosystems, Inc., a leading innovator and worldwide provider of automated sample management systems, announced the signing of an agreement to acquire REMP AG, a wholly-owned subsidiary of Tecan, as well as other related assets.

Under this agreement, Nexus will acquire all activities of Tecan's REMP Sample Management business segment from Tecan. REMP, based in Oberdiessbach, Switzerland, is a leading global provider of sample management systems and related sample management devices, instruments and consumables. In parallel with this transaction, Tecan and Nexus plan to collaborate on various additional product groups. The transaction should be closed within the next 2 months.

John Lillig, CEO of Nexus Biosystems, commented: "We are delighted with the opportunity to broaden our automated chemical and biological sample management offerings with the acquisition of Tecan's REMP Sample Management business. Together with our new colleagues from REMP, we look forward to continuing to provide innovative and reliable sample management solutions for our customers in the biopharmaceutical, biorepository, diagnostic, forensic, agrochemical and genomic research centres throughout the world. The combined Nexus -REMP resources will strengthen our capabilities and ensure continuity of first-class service and support for our customers as well as expand our product offerings for the growing global sample management community. As a key part of this opportunity we also look forward to furthering our collaborations with our colleagues at Tecan."

Thomas Bachmann, CEO of Tecan, commented: "We are certain that the sale of REMP to Nexus Biosystems is the ideal solution. Our customers will benefit from the strong global market and service presence and the unparalleled innovation strength of the combined Nexus -REMP entity in this industry segment. At Tecan, we will focus resources on growth projects in our traditional core markets and actively expand our end-customer business and our OEM activities."

Nexus Biosystems is one of the world's leading providers of automated sample management systems and technologies for the biopharmaceutical, biorepository and related research communities around the world. Nexus' majority investor is Telegraph Hill Partners, a life science and medical products growth equity investment company based in San Francisco (California, USA).

Nexus and REMP complement one another, with Nexus having strengths in high speed, mid-size sample management systems and high performance microtiter plates, while REMP is a leader in small and large size automated sample management systems and high quality sample containers and consumables. REMP has a strong customer base in Europe and Asia with a growing presence in the USA, while Nexus enjoys a strong position in the USA with a growing presence in Europe and Asia.

Nexus Biosystems is a leading innovator and worldwide provider of enabling technologies and automated sample management systems for pharmaceutical, biotech, biorepository, agrochemical and related research institutions worldwide.

Tecan is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector.